“If the ice is clear, you can sometimes see snapping or painted turtles moving slowly under the ice,” said Jeff LeClere, ...

Microrobot swarms self-assemble into artificial microtubules under confinement, moving cargo through tight channels and ...

The surgery went smoothly, the patient is now awake, vital signs are stable, able to eat and drink; the twins are stable with ...

Q32 Bio shares rise after selling ADX-097 to Akebia in a deal worth up to $592 million, boosting cash runway into late 2027.

Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, ...

Akebia filed its Investigational New Drug Application with the U.S. Food and Drug Administration (FDA) and recently initiated ...

Maintaining good leg circulation is vital for overall vascular health, preventing issues like swelling and pain. Natural approaches include exercise, ...

A new study published in BMC Surgery compared minimally invasive complete mesocolic excision with conventional right ...

Venous leg ulcers are a preventable and treatable condition, yet hundreds of thousands of people continue to suffer ...

Skin manifestations of liver diseases are varied and serve as warning signals for the underlying pathology. Early recognition ...

As the US president takes another savage swipe at a female reporter and questions over his health ramp up, we look at the ...

Investing.com -- Q32 Bio Inc (NASDAQ:QTTB) stock surged 94% in premarket trading Monday after the clinical-stage biotechnology company announced the sale of its Phase 2 complement inhibitor, ADX-097, ...